17:56 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

Protagonist discontinues Phase IIb of PTG-100 for UC

Protagonist Therapeutics Inc. (NASDAQ:PTGX) discontinued the Phase IIb PROPEL trial of once-daily PTG-100 to treat moderate to severe ulcerative colitis. Protagonist said it will decide whether to start a Phase II/III trial of the candidate...
18:13 , Mar 26, 2018 |  BC Extra  |  Clinical News

Protagonist shares halved on UC failure

Protagonist Therapeutics Inc. (NASDAQ:PTGX) was down $11.68 (57%) to $8.75 on Monday after the company discontinued the Phase IIb PROPEL trial of PTG-100 to treat moderate to severe ulcerative colitis. Protagonist said it will decide...
21:45 , Jun 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Pumping iron

A natural compound from the Japanese Hinoki tree may hold the answer to iron transport diseases treated inadequately by phlebotomy, chelation therapy or dietary supplements. In...
05:21 , Mar 3, 2017 |  BC Week In Review  |  Company News

Pieris, Aska deal

Pieris granted Aska an exclusive option to develop and commercialize PRS-080 in Japan, South Korea and undisclosed other Asian markets outside of China. Pieris will receive $2.8 million up front. If the option is exercised,...
23:51 , Nov 21, 2016 |  BioCentury  |  Product Development

AML Takes ASH

An analysis of the nearly 5,000 abstracts to be presented at the American Society of Hematology meeting shows research on acute myelogenous leukemia will dominate. BioCentury analyzed more than 2,200 abstracts concerning clinical research, including...
23:02 , Nov 17, 2016 |  BC Innovations  |  Product R&D

Hemorrhaging targets

An analysis of the almost 5,000 abstracts set to be presented at the 2016 American Society of Hematology (ASH) meeting next month indicates this year’s hot topics in preclinical research include a spattering of new...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

LJPC-401: Phase I data

An open-label, dose-escalation Phase I trial in 15 patients at risk of iron overload showed that single doses of 1-20 mg subcutaneous LJPC-401 dose-dependently and significantly reduced mean serum iron levels from baseline to 8...
07:00 , Aug 15, 2016 |  BioCentury  |  Finance

Serving returns

China's Ally Bridge Group hit the investment world's radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that...
08:00 , Jan 7, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Hepcidin; solute carrier family 40 iron-regulated transporter member 1 (SLC40A1; SLC11A3)

Hematology INDICATION: Hematology In vitro, animal and human sample studies identified three steroids that could treat iron overload by promoting expression of hepcidin , an inhibitor of the iron transport protein SLC40A1 . Screening of...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

Roxadustat: Phase II data

An open-label Phase II trial in 60 incident dialysis CKD patients not receiving erythropoietin-stimulating agent (ESA) therapy showed that thrice-daily oral roxadustat for 12 weeks increased mean maximum hemoglobin, the primary endpoint, by 3.1 g/dL....